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Up to than 90% of people with dementia will experience behavioural and psychological 
symptoms of dementia (BPSD) as part of their illness, and nearly two thirds of those living 
with dementia in care homes will experience BPSD. BPSD describes the disturbed perceptions, 
thought content, moods or behaviours that frequently occur in patients with dementia. There 
is increasing evidence that the gut microbiota plays a role in the interaction between specific 
nutrients and brain function. The Ageing Gut-Brain study described here is based on the 
hypothesis that the gut microbiota, and microbial metabolites, impact upon the gut-brain axis 
and thereby on behaviour, including BPSD. In the absence of available cures for Alzheimer's 
disease and its symptoms, if evidence in support of the gut-brain axis hypothesis is found, 
diet/nutritional interventions comprising important modifiable component/s may have 
significant impact on the management of BPSD.  
 











With a growing number of ageing populations across the world, healthy life expectancy is a 
key area of research. One of the major health challenges in recent years is the alarming rise 
in the prevalence of non-communicable diseases including dementia. In Europe, the age-
adjusted prevalence of dementia of any kind among people aged 65 years and older is 6.4% 
and of Alzheimer’s disease (AD) specifically 4.4% (Lobo et al. 2000; McVeigh & Passmore  
2006). It has been estimated that 36 million people have dementia worldwide (Prince et al. 
2013) and that there are 4.6 million new cases of dementia every year (Ferri et al. 2005). 
Epidemiological evidence supports the hypothesis that modifiable lifestyle-related factors are 
associated with cognitive decline, which opens new avenues for prevention (Solfrizzi et al. 
2008).  
Alzheimer's disease is the commonest cause of dementia in older people, accounting 
for 60–70% of all dementia cases when using traditional diagnostic criteria for dementia 
subtypes (Fratiglioni et al. 1999; Blennow et al. 2006). There are no available cures for AD;  an 
alternative approach is to use strategies that delay disease progression at an early stage (Lobo 
et al. 2000). Optimal brain function results from highly complex interactions between 
numerous genetic and environmental factors, including food intake, physical activity, age and 
stress (Solfrizz et al. 2008). Future studies linking nutrition with advances in neuroscience and 
‘omics’ technologies might provide novel approaches to the prevention of cognitive decline, 
and treatment of dementia and AD. Diet in particular has become the object of intense 
research in relation to cognitive ageing and neurodegenerative diseases.  
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Behavioural and psychological symptoms of dementia  
During the course of dementia the vast majority of people will experience some form of 
behavioural or psychological symptoms of dementia (BPSD). BPSD are central to dementia 
syndromes and seen in between 50% and 90% of patients with dementia at some point during 
their lifetime (Ballard & Waite 2006; Cerejeira et al. 2012), with higher prevalence in hospital 
and long-term residential care facilities in comparison to community dwelling settings. These 
symptoms can result in significant reduction in quality of life, are a major source of caregiver 
stress and increase financial burden through the requirement for institutional care. BPSD 
include agitation, aggression, calling out repeatedly, sleep disturbance, and lack of interest 
and motivation. Numerous studies have reported that BPSD can be a major source of distress 
for family and caregivers and are an important predictor of family caregiver depression, 
burden and care home admission (Porter et al. 2016). The degree and presentation of BPSD  
varies, depending on dementia severity, brain-damaged state and aetiology of the dementia 
syndrome (Cerejeira et al. 2012). It has been suggested that the physiological basis for BPSD 
relates to an imbalance of neurotransmitters including acetylcholine, dopamine, 
noradrenaline, serotonin and gamma-Aminobutyric acid (GABA) (Perry et al. 2003). 
Differences in the presentation of BPSD between pathological subtypes of dementia are likely 
to be partially explained by the different neurophysiological changes associated with each 
subtype (Cerejeira et al. 2012).  
Many dementia syndromes have no modern therapeutic treatments, and there is little 
evidence that treatments that are given help to manage symptoms. Psychosocial therapies 
and antipsychotic medications are commonly used in an attempt to manage symptoms, with 
over 40% of patients with dementia in institutional care receiving antipsychotic medications 
(Maust et al. 2015). There is a risk of harm from antipsychotic drug use: falls and drowsiness 
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are common. More serious adverse effects include accelerated cognitive decline, and 
increased risk of arrhythmia and stroke. The use of antipsychotics in patients with dementia 
has also been shown to be associated an increased mortality risk of up to 3.8% (Maust et al. 
2015). 
In the absence of available cures for dementia syndromes, and with a lack of safe and 
effective treatments for the neuropsychiatric symptoms associated with the advanced stages 
of dementia, there is increased interest in whether dietary modifications can offer benefits. 
However, there is currenly little knowledge about the role of diet and dietary supplements in 
management of clinical symptoms of dementia. It has been hypothesised that the gut-brain 
axis plays a central role in BPSD, with emerging research suggesting a relationship between 
cognitive ageing and neurodegenerative diseases and the gut microbiota (Mariat et al. 2009; 
Claesson et al. 2012). 
Gut microbiota in the older adult  
The physiology and functioning of the gastrointestinal (GI) tract and diet change with age, and 
this impacts on the composition of the gut microbiota (O’Toole & Jeffery 2015). Fraility, rather 
than chronological age, has been found to correlate with changes in the microbiota in 
community-dwelling older adults (Fried et al. 2001). Maintaining a ‘younger-adult’ diverse 
microbiota, as a result of a diverse diet, may protect against fraility and poor health. For 
example, Italian semi-supercentenarians (those aged 105 – 109), with a lower incidence of 
chronic diseases that generally affect the elderly, were found to have different but still diverse 
microbiota in comparison to in comparison to adults, elderly adults, and centenarians (Biagi 
et al. 2016). Two studies that profiled the gut microbiota in the elderly, comparing free-living 
and care-home residents, demonstrated significant relationships between microbiome 
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profiles and indices of frailty and poor health (Jackson et al. 2016, Jeffery et al. 2016). Changes 
in dietary composition and diversity were considered the main drivers of the shifts in gut 
bacteria profile. As these studies are correlational, evidence from randomised controlled 
trials (RCTs) is required to understand whether a diverse microbiota is a cause or consequence 
of fraility and poor health in the elderly (Caracciolo et al. 2014). Age-related changes in the 
gut microbiota can contribute to the onset and progression of inflammation associated with 
ageing by increasing the production of a number of pro-inflammatory mediators, or lowering 
production of those that are anti-inflammatory, thus tilting the equilibrium toward 
inflammation (O’Toole & Jeffery 2015). The studies comparing the microbial profile of frail 
elderly to that of healthy elderly show that bacterial species associated with inflammation are 
more prevalent in the former group (O’Toole 2012).  
Research focussed specifically on AD has shown that increases in levels of neurotoxic 
proteins in the brain (amyloid formation) and circulating pro-inflammatory cytokines 
correlate with a lower abundance of the butyrate–producing anti-inflammatory bacterium 
Eubacterium rectale and higher levels of pro-inflammatory Escherichia coli/Shigella (Cattaneo 
et al. 2017). As neuro-inflammation is associated with cognitive decline (Solas et al. 2017), 
this is an important finding but research is needed to understand the direction fo the 
relationship between neuro-inflammation and the composition of the gut microbiota.  
There are numerous potential pathways through which the activity of the gut 
microbiota may influence the brain (sumarised in Figure 1). These include direct effects of gut 
microbiota metabolites [e.g. short-chain fatty acids (SCFA), 5-hydroxytryptamine (5-HT) 
acetylcholine, gamma-aminobutyric acid (GABA), serotonin], neural routes (vagus and enteric 
nervous systems), the adrenal axis (cortisol), and cytokines via their effect on immune cells. 
Any change to the balance of the gut microbiome could therefore alter the signals received 
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by the brain, potentially affecting emotions, mood and behaviour. Under conditions of stress, 
the brain can also send signals to the gut via the adrenal axis and vagus nerve.    
Dietary modification as a potential strategy for the treatment of Alzheimer’s disease  
A number of human intervention studies have shown rapid changes in the gut microbiota 
composition following dietary modification, with concomitant changes in production of 
bacterial metabolites. For example, reduced carbohydrate diets have been linked with lower 
bacterial production of SCFAs, particularly butyrate, and a reduction in the numbers of 
butyrate producing bacteria (Duncan et al. 2007; Walker et al. 2011). However, there is a need 
to understand the underlying mechanisms which could potentially link diet-induced 
microbiota changes to changes behaviour, such as BPSD. 
The degenerative diseases associated with ageing are frequently linked to oxidative 
stress and inflammation, and inflammation in the gut is linked to changes in microbiota 
composition (see review by Vaiserman et al. 2017). Many probiotic bacteria are lactic acid 
bacteria, some of which have antioxidant and immune regulatory activities (Lee et al. 2016). 
In a mouse model of ageing, oxidative stress (measured by monitoring levels of hepatic anti-
oxidant enzymes in the liver) was reduced, and the microbial composition and activity 
restored to that of the control group, by adding Lactobacillus helveticus by daily oral gavage 
for 8 weeks (Li et al. 2018). Several other small animal studies have explored brain function 
following probiotic supplementation, with improvements demonstrated for different aspects 
of memory impairments following different triggers (e.g. Beilharz et al. 2018; Chunchai et al. 
2018, O’hagan et al. 2017), but limited research has been conducted in humans. In one study, 
a mixture of three lactobacilli strains plus a Bifidobacterium bifidum strain consumed daily in 
probiotic milk for 12 weeks improved cognitive function in AD patients (Akbari et al. 2016), 
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but had little effect on markers of oxidative stress and inflammation, only serum high 
sensitivity C-reactive protein (hs-CRP) and malondialdehyde (MDA) decreased. In another 
study, the abundance of bifidobacteria in elderly individuals was increased following 
bifidobacteria administration, with a concomitant lowering in the levels of pro-inflammatory 
cytokines and increases in anti-inflammatory cytokines (Ouwehand et al. 2008). The study 
assessed only the levels of specific cytokines and the bifidobacteria component of the 
microbiota, and did not include any cognitive or behavioural outcome measures. A recent 
review that focussed on the role of the gut microbiota in neurogenerative disorders (Sarkar 
& Banerjee 2019) concluded that while research indicate a potential role for probiotics in AD, 
cognition and inflammation, more research is required to understand the mechanisms.  
 
Other studies have focussed on using prebiotic strategies to modulate the microbiota with 
the aim of increasing the bacterial diversity and altering parameters associated with ageing. 
For example, daily supplementation with a mixture of five prebiotics (at 20 g/ day) for 6 
months did not have the expected effect of increased bacterial diversity in a study comparing 
cohorts of healthy adults, elderly adults (70+ years) and elderly adults in long-stay 
environments (80+ years), although small specific effects on some bacterial families and a 
decrease in the inflammatory cytokine CCL11 were observed following the prebiotic 
intervention (Tran et al. 2019). The authors noted that it was difficult to achieve compliance 
in the elderly cohort due to the perceived negative side effects associated with increased fibre 
consumption. Compliance is likely to be an issue that all  dietary studies in the elderly will 
have to negotiate. In another prebiotic intervention trial in  older individuals without 
dementia (70+ years) living in carehomes, consumption of a fructo-oligosaccharide/inulin 
supplement for 13 weeks resulted in a reduction in frailty levels, as assessed by a combination 
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score, in participants with the highest initial levels of frailty. In this study, there was no 
assement of the effects of the intervention on  the particpants’ microbiota profile or 
inflammatory markers (Theou et al. 2019).     
 
Two ongoing studies are investigating the effects of dietary interventions on cognition in older 
adults. A trial in the US in 200 adults aged 55 – 75 years is exploring the effect of a probiotic 
Lactobacillus species (specifically LGG) on mood and cognitive functioning , as well as the gut 
microbiota composition and blood markers of inflammation (Sanbornet al. 2018). In an 
Australian trial with 400 older participants aged 60 – 75 years, the effects of daily 
consumption of two different herbal supplements and a placebo on cognitive performance 
are being compared. The study will include neuroimaging and assessment of the participants’ 
faecal microbiota composition (Stough et al. 2012; Simpson et al. 2019). 
 
Overview of Ageing-Gut Brain Interactions Study 
Potential mechanisms underpinning the hypothesised bi-directional signalling between the 
brain and gut are outlined in Figure 1. At present it is unclear if modifying the gut microbiota 
profile through dietary changes can help prevent or treat neurological conditions, such as 
dementia. There has been no published work that we are aware of to examine the gut 
microbiota profile in patients with AD with associated BPSD. With increasing evidence that 
the gut microbiota may mediate the interaction between nutrition and brain function and 
that the composition of the microbiota correlates with diet and health in the elderly, the 
Ageing Gut-Brain project is designed to explore the role of the gut microbiota in BPSD in AD.  
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The Ageing Gut-Brain project has been funded by Tenovus Scotland, the NHS 
Grampian Research and Endowments Fund, and the Scottish Government as part of the 
Strategic Research Programme at the Rowett Institute. The project commenced in March 
2018 and is expected to be completed at the end of 2019.  The main aim of this proof-of-
concept study is to explore whether gut microbiota profiles, assessed from faecal samples, 
differ among three participant groups: (1) dementia with BPSD, (2) dementia without BPSD 
and (3) healthy age-matched controls. Studying those living only in a care home environment 
means there is likely to be less dietary diversity between participants, a confounding factor 
affecting the gut microbial composition. Data collected as part of the Ageing Gut-Brain study 
will inform a future dietary intervention study to tease out the complex relationship between 
diet, the gut microbiome and BPSD in AD. Our ultimate ambition is to develop evidence-based 
dietary and lifestyle recommendations for people with AD plus BPSD, to reduce the burden 
of this condition on patients, family and society, and create safer environments for carers and 
society generally.  
Ageing Gut-Brain project: Hypothesis and aims  
The Ageing Gut-Brain proof-of concept study will test the hypothesis that differences exist in 
the gut microbiota profiles and activity of its metabolites between normal healthy ageing 
participants and those with dementia, with a focus on those with challenging behaviour 
consistent with BPSD. In addition, the study will gather information on the feasibility and 
acceptability of a future nutritional intervention trial in this population group. The project 
aims are summarised in Figure 2 and sample collection protocol summarised in Figure 3.  
The five study aims are:  
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• Aim 1: To assess care homes’ willingness to participate in a dietary intervention to 
reduce the burden of BPSD in AD.  
• Aim 2: To test the feasibility of recruitment in older populations with or without 
dementia in residential care facilities, including the practicalities of faecal sample 
collection and working in the care home environment. 
• Aim 3: To test the hypothesis that the gut microbiota profile is different among three 
groups of older people with (1) no dementia, (2) with AD and BPSD and (3) with AD 
but without BPSD, living in the same environment.  
• Aim 4: To assess the willingness of older people with AD (with or without BPSD) and 
their carers (formal or informal) to participate in the proposed future nutritional 
intervention trial and the practical feasibility of assessing quality of life in this cohort. 
• Aim 5: To measure dietary intake in the study cohort.  
 
Ageing Gut-Brain project: Methods of research  
To achieve Aim 1, we carried out a survey using Survey Monkey. The survey link was 
distributed via email to all Scottish care homes known to the ‘Neuroprogressive and Dementia 
Network’, and remained open for a month in June 2018.   In summary, there were 105 
responses representing approximately 95% of Scottish postcode areas. Eighty one percent of 
respondents completing the full survey and 83% of responses were from care home 
managers.  The median % of care home residents with any type of dementia was 70.2% 
(interquartile range: 51.3-84.7%), and the median % of those with dementia with challenging 
behaviours was 34.8% (interquartile range: 17.4-50.0%). The usual immediate step taken by 
care home staff to help residents exhibiting challenging behaviour are shown in Figure 4. 
Challenging behaviours are recorded on ‘ABC’ (Antecedent, Behaviour, Consequences) charts 
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in 80% of care homes. Care home staff were positive about researchers approaching their 
care home to conduct a dietary intervention in those with challenging behaviours, with 62% 
of those responding ≥80% likely to say yes to the research being conducted.  More than 90% 
of care homes stated that they would require information on staff time and staff training 
requirements before commiting to become a study site. Care homes have great potential for 
hosting research into dietary components affecting AD progression.  While most respondents 
showed a high level of support for research in their care homes, researchers will need to 
design studies with the high demands on care home staff time in mind (Johnstone & 
Donaldson, 2019). 
 
To achieve aims 2 and 3, 20 volunteers from each of the three study groups (60 in total) will 
provide two faecal samples, at least a week apart for validation purpose (to examine the 
within-subject variation for this cohort). These will be analysed for microbial composition and 
metabolic activity by assessing SCFA profiles. Faecal samples will be collected using a pot on 
a toilet/commode, or incontinence pad, which will be sealed and processed in the laboratory 
within 16 hours.  To confirm group allocation, care home staff will be asked to log any 
episodes which require staff intervention due to challenging behaviours.  We will collect 
additional information to mitigate the confounding effects of medication (especially antibiotic 
use), personal characteristics, co-morbidities, and active GI disease.   
To achieve aim 4, we will collect information on the following to explore the practical 
feasabilities and willingness of older people with AD and their carers to participate in a future 
intervention study: 
• proportion of eligible older people with dementia with or without challenging 
behaviors (BPSD);  
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• proportion of eligible participants willing to participate;  
• proportion of participants who are able to provide samples in each group;  
• proportion of participants (or nearest relative, welfare guardian or welfare attorney) 
who are able to provide study data /information; and 
• quality of life for those with dementia using a validated questionnaire.).  
We intend to survey staff, next of kin and participants (whenever feasible) to explore their 
experiences with the proof-of-concept study and issues of acceptability. 
The assessment of dietary intake in  elderly participants with dementia, even in the care home 
environment, is challenging as the usual self-report restrospective recall methods (via food 
diaries, food frequency questionnaires) are not appropriate for use in this population group. 
Therefore, to achieve aim 5, the Ageing Gut-Brain study will assess dietary intakes by 
obtaining care-home menu records, accepting there are a number of major limitations with 
this approach.   
 
Conclusions 
The Ageing Gut-Brain study aims to increase understanding of the relationship between the 
gut microbiotia composition and BPSD in AD.  A future intervention study will explore whether 
dietary modification can change the gut microbiota and alleviate signs and symptoms of 
dementia in this vulnerable group, and therefore improve quality of life and reduce carer 
stress.  This work has the potential to open opportunities for lifescience companies and small-
to-medium size businesses to exploit mechanistically relevant biomarkers of BPSD in AD, and 
for industrial markets (from agriculture to food industry) and specialist caterers to develop 
healthy foods/diets that are tailored to the specific needs of an ageing population.  
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Cognitive and behavioural problems in dementia can result in reduced appetite, increased 
physical activity, and the disruption of eating and feeding behaviours, all of which can reduce 
quality of life, increase risk of hospital admissions, morbidity (e.g. falls) and early mortality. 
Thus, it is expected that a targeted nutritional strategy could result in a number of wider 
health benefits.  In future, we envisage investigating how dietary adjustments could promote 
healthier ageing in vulnerable older adults who are at risk of dementia due to cognitive deficit 
but who do not yet have a dementia diagnosis.  
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Figure 1: Potential mechanisms underpinning the hypothesised bi-directional signalling 
between the brain and the gut. SCFA, short chain fatty acid; GABA, gamma-Aminobutyric 
acid ; 5-HT, 5-hydroxytryptamine 
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Figure 2: Aims of the Ageing Gut-Brain study 
Figure 3: Sample collection protocol for the Ageing Gut-Brain study 
Figure 4 : Initial response by care home staff to a resident displaying challenging behaviour. 
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